

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

23 May 2019 (23.05.2019)



(10) International Publication Number

WO 2019/096327 A1

(51) International Patent Classification:

C07D 215/44 (2006.01) A61P 35/00 (2006.01)
A61K 31/4706 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/CN2018/116484

(22) International Filing Date:

20 November 2018 (20.11.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/707,816 20 November 2017 (20.11.2017) US

(71) Applicant: TELIGENE LTD [CN/CN]; 218 Xinghu St.,
A4 Building, 416, Suzhou Industrial Park, Suzhou, Jiangsu
215123 (CN).

(72) Inventor: ZHANG, Dawei; 218 Xinghu St., A4 Building,
416, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).

(74) Agent: AFD CHINA INTELLECTUAL PROPERTY
LAW OFFICE; Suite B 1601A, 8 Xue Qing Rd., Haidian
District, Beijing 100192 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

(54) Title: MALEATE SALTS OF (E)-N-(3-CYANO-7-ETHOXY-4-((4-PHENOXYPHENYL)AMINO) QUINOLIN-6-YL)-4-(DIMETHYLAMINO) BUT-2-ENAMIDE AND CRYSTALLINE FORMS THEREOF

(57) Abstract: The present application relates to maleate salts of (E) -N- {4- [3-chloro-4- (2-pyridinylmethoxy) aniline] -3-cyano-7-ethoxy-6-quinolinyl} -4- (dimethylamino) -2-butenamide, crystalline forms thereof, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders.



WO 2019/096327 A1

**MALEATE SALTS OF
(E)-N-(3-CYANO-7-ETHOXY-4-((4-PHENOXYPHENYL)AMINO)
QUINOLIN-6-YL)-4-(DIMETHYLAMINO)BUT-2-ENAMIDE AND
CRYSTALLINE FORMS THEREOF**

5

RELATED APPLICATION

[0001] The present application claims the benefit of U.S. Provisional Patent Application No. 62/707,816, filed on November 20, 2017, which is incorporated herein by reference in its entirety.

10

FIELD OF THE INVENTION

[0002] The present application relates to maleate salts of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide, crystalline forms thereof, methods of preparing the salts, associated compounds, pharmaceutical compositions containing the maleate salt, and methods for their use. Maleate salts of


15 (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide are useful in the treatment of cancer.

BACKGROUND OF THE INVENTION

[0003] (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide is mentioned in WO2013152135 and corresponds to the compound of the Formula I:

20

Formula I



25

[0004] Compounds derived from 3-cyanoquinoline have been shown to have anti-tumor activity, which may make them useful as chemotherapeutic agents in treating various cancers, including but not limited to, pancreatic cancer, melanoma, lymphatic cancer, parotid tumors, Barrett's esophagus, esophageal carcinomas, head and neck tumors, ovarian cancer, breast cancer, epidermoid tumors, cancers of major organs, such as kidney, bladder, larynx, stomach,

and lung, colonic polyps and colorectal cancer and prostate cancer. Examples of compounds derived from 3-cyanoquinoline are disclosed and shown to possess anti-tumor activity in many literatures. One limitation of certain 3-cyanoquinoline compounds is that they are not water soluble in a free base form.

5 [0005] The crystalline form of a particular drug as a salt, a hydrate and/or any polymorph thereof is often one important determinant of the drug's ease of preparation, stability, water solubility, storage stability, ease of formulation and *in-vivo* pharmacology. It is possible that one crystalline form is preferable over another where certain aspects such as ease of preparation, stability, water solubility and/or superior pharmacokinetics are deemed to be critical.

10 Crystalline forms of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide salts that possess a higher degree of water solubility than the free base but are stable fulfill an unmet need for stable, crystalline, water-soluble forms of substituted 3-cyanoquinoline compounds that selectively inhibit kinase activity, which in turn inhibit cell proliferation and tumorigenesis.

SUMMARY OF THE INVENTION

[0006] In one aspect, the present application provides a maleate salt of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide. In a particular aspect, the present application provides (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate monohydrate.

20 In another particular aspect, the present application provides crystalline forms of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate, which have been isolated and characterized as: an anhydrous form, a monohydrate form, and a mixture of the anhydrous and the monohydrate forms (referred to as a partial hydrate form).

25 [0007] In another aspect, the application provides methods for the preparing ((E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide as a maleate salt including monohydrate thereof.

[0008] In another aspect, the application provides pharmaceutical compositions comprising a maleate salt of ((E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide and monohydrate thereof.

30

[0009] In another aspect, the application provides methods for preventing or inhibiting cancer in a subject comprising administering the subject a therapeutically effective amount of

a maleate salt of ((E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide and monohydrate thereof.

BRIEF DESCRIPTION OF DRAWINGS

[0010] FIG. 1: PXRD of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide maleate salt monohydrate crystalline (Form I);

[0011] FIG. 2: DSC thermogram of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide maleate salt monohydrate;

[0012] FIG. 3: PXRD of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide maleate salt crystalline (Form II);

[0013] FIG. 4: TGA thermogram of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide maleate salt monohydrate;

[0014] FIG. 5: IR spectrum of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide maleate salt monohydrate;

[0015] FIG. 6: PXRD of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide hydrochloride acid salt;

[0016] FIG. 7: PXRD of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide citrate salt;


[0017] FIG. 8: PXRD of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide L-malate salt;

[0018] FIG. 9: PXRD of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide sulphate salt.

DETAILED DESCRIPTION OF THE INVENTION

[0019] (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide is an irreversible inhibitor to BTK and Her-2 (also known as Erb-2 or neu) kinase, a member of the epidermal growth factor receptor (EGFR) family. EGFR family members have been implicated in tumorigenesis and associated with poor prognosis in tumor types in humans. The structure of the (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide in the form of a free base is shown below:

Formula I



[0020] The compound (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide in the form of a free base is described in WO2013152135. There is a need for a form of this compound with improved physicochemical properties, and better bioavailability.

[0021] In some embodiments, the application provides a maleate salt of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide.

[0022] In some embodiments, the application provides a maleate salt of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide which is a 1 : 1 molar ratio of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide to maleic acid.

[0023] In some embodiments, the present application provides (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate monohydrate.

[0024] In some embodiments, the present application provides (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate, which have been isolated and characterized as: an anhydrous form, a monohydrate form, and a mixture of the anhydrous and the monohydrate forms (referred to as a partial hydrate form).

[0025] In some embodiments, the present application provides crystalline forms of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate, which have been isolated and characterized as: an anhydrous form, a monohydrate form, and a mixture of the anhydrous and the monohydrate forms (referred to as a partial hydrate form).

[0026] In some embodiments, the present application provides a crystalline form (Form II) of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate, which is characterized by its powder X-ray diffraction (PXRD) pattern having characteristic peaks at about 8.1, 15.0, 17.6, and 23.6 degree of 2θ (± 0.2). The crystalline Form II of the application is further characterized by its PXRD having additional

peaks at about 9.0, , 18.5, 22.7, 23.0, and 25.1. The crystalline Form II of the application is characterized by its PXRD having essentially the same as shown in FIG. 3.

[0027] In some embodiments, the present application provides a crystalline form (Form I) of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate monohydrate, which is characterized by its powder X-ray diffraction (PXRD) pattern having characteristic peaks at about 15.5, 16.8, 20.9, 24.4, 25.2 and 26.5 degree of 2θ (±0.2). The crystalline Form I of the application is further characterized by its PXRD having additional peaks at about 8.7, 9.8, 14.3, 17.4, 19.3, 19.8, and 23.8. The crystalline Form I of the application is characterized by its PXRD having essentially the same as shown in FIG. 1.

[0028] In some embodiments, the present application provides a crystalline form (Form I) of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate monohydrate, which is characterized by its differential scanning calorimetry (DSC) thermogram having two endothermic peaks between about 153 °C and about 180 °C. The crystalline Form I of the application is characterized by its DSC thermogram having essentially the same as shown in FIG. 2.

[0029] In some embodiments, the present application provides a crystalline form (Form I) of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate monohydrate, which is characterized by its infrared spectroscopy (IR) comprising one or more peaks at about 3507.20, 3326.14, 3036.83, 2995.35, 2938.83, 2640.50, 2417.18, 2214.77, 1847.62, 1686.72, 1620.70, 1581.83, 1539.15, 1485.39, 1459.27, 1386.91, 1349.85, 1278.17, 1226.56, 1163.32, 1113.32, 1078.80, 1034.16, 979.59, 866.53, 829.88, 747.82, 700.14, 662.23, 556.48, and 487.55 cm⁻¹. The crystalline Form I of the application is characterized by its IR having essentially the same as shown in FIG. 5.

[0030] In some embodiments, the application provides methods for the preparing a maleate salt of ((E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide comprising the step of: mixing ((E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide and maleic acid in a water-alcohol solution or an alcohol solution at an elevated temperature. The methods further include the steps of: cooling said solution to precipitate maleate salt, and filtering and drying.

[0031] In some embodiments, the said alcohol is selected from one or more of methanol, ethanol, n-propanol, and isopropanol.

[0032] In some embodiments, the application provides a method of preparing (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-

enamide maleate monohydrate comprising the steps selected from the group consisting of: a. dissolving anhydrous (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate with an organic solvent, adding water, and filtering; b. dissolving anhydrous (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate with an organic solvent, adding a solution of a second organic solvent and water, and filtering; c. dissolving anhydrous (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate with an organic solvent containing water, and filtering; and d. reslurrying anhydrous (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate with an organic solvent containing water for a period of days, and filtering; e. dissolving anhydrous ((E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate with water, and filtering.

[0033] In some embodiments, the said organic solvent is selected from one or more of methanol, ethanol, n-propanol, and isopropanol

[0034] In some embodiments, the application provides methods for preventing or inhibiting cancer in a subject comprising administering the subject a therapeutically effective amount of a maleate salt of ((E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide and monohydrate thereof. The maleate salts and crystalline forms of the present application are useful for preventing, treating, or inhibiting inflammation or cancer by administering a therapeutically-effective amount of compound (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate or crystalline forms thereof to a subject. The subject may be a mammal, and more specifically, a human. The maleate salt may be administered in its anhydrous form, monohydrate form or partially hydrated form. Crystalline forms of the maleate salts of the present application are useful for preparing pharmaceutical compositions for the inhibition of BTK and/or HER-2 kinase activity, effective amount of compound (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate and a pharmaceutically acceptable carrier. The pharmaceutical composition may be administered in its anhydrous form, monohydrate form or partially hydrated form.

[0035] Pharmaceutical compositions and formulations of the present application may be useful in the treatment of one or more of breast cancer, ovarian cancer, epidermoid tumors, colon cancer, prostate cancer, kidney cancer, bladder cancer, larynx cancer, esophagus cancer, stomach cancer, lung cancer, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse

large B-cell lymphoma, or multiple myeloma. According to one embodiment, the maleate salt is particularly useful in the treatment of breast cancer and/or ovarian cancer.

[0036] In some embodiments, the application provides pharmaceutical compositions comprising a maleate salt of ((E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide or monohydrate, or crystalline forms thereof.

[0037] The pharmaceutical compositions and formulations including maleate salt forms of the application may be administered orally, by intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; liposome-mediated delivery; topical, nasal, anal, vaginal, sublingual, urethral, transdermal, intrathecal, ocular or otic delivery. One mode of administration for the compound of the application is the unit dose form. Suitable unit dose forms include tablets, capsules and powders in sachets or vials. The crystalline compounds of the present application can be administered orally. Such compounds may be administered from 1 to 6 times a day more usually from 1 to 4 times a day. The effective amount will be known to one of skill in the art; it may also be dependent upon the form of the compound, the mode of administration and the severity of the condition being treated. One of skill in the art could routinely perform empirical activity tests to determine the bioactivity of the compound in bioassays and thus determine what dosage to administer. However, in general, satisfactory results can be obtained with compounds of the present application when dosed daily in the range of about 0.5 mg/kg to about 1000 mg/kg of body weight, but usually the effective dosage amount is between about 1mg/kg to about 300 mg/kg per day.

[0038] The crystalline forms of maleate salts of the application may be formulated with conventional excipients, such as fillers, disintegrating agents, binders, lubricants, flavoring agents, color additives, and carriers. The carrier may be a diluent, an aerosol, a topical carrier, an aqueous solution, a nonaqueous solution or a solid. The carrier may be a polymer or a toothpaste. A carrier in this application encompasses any of the standard pharmaceutically accepted carriers, such as phosphate buffered saline solution, acetate buffered saline solution, water, emulsions such as an oil/water emulsion or a triglyceride emulsion, various types of wetting agents, tablets, coated tablets and capsules. If administered orally or topically, the crystalline forms of maleate salts of the application may be provided to a subject in different carriers. Typically, such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid, talc, vegetable fats or oils, gums, or glycols. Specific carriers are typically selected based upon the desired method of delivery, for example, phosphate buffered saline (PBS) could be used for intravenous or systemic delivery and vegetable fats, creams,

salves, ointments or gels may be used for topical delivery. The crystalline forms of maleate salts of the present application may be delivered together with suitable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers useful in treatment, inhibition or prevention of neoplasm. Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (for example, TrisHCl, acetate, phosphate), pH and ionic strength, additives such as albumins or gelatin to prevent absorption to surfaces, detergents (for example, TWEENTM 20, TWEENTM 80, PLURONICTM F68, bile acid salts), solubilizing agents (for example, glycerol, polyethylene glycerol), anti-oxidants (for example ascorbic acid, sodium metabisulfate), preservatives (for example, thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (for example, lactose, mannitol), covalent attachment of polymers such as polyethylene glycol, complexation with metal ions, or incorporation of the compound into or onto particulate preparations of hydrogels or liposomes, micro-emulsions, micelles, unilamellar or multi lamellar vesicles, erythrocyte ghosts, or spheroblasts. Such compositions will influence the physical state, solubility, stability, rate of *in vivo* release, and rate of *in-vivo* clearance of the compound or composition. The choice of compositions will depend on the physical and chemical properties of the compound. The crystalline forms of maleate salts of the application also may be delivered locally via a capsule that allows a sustained release of the compound over a period of time. Controlled or sustained release compositions include formulations in lipophilic depots (for example, fatty acids, waxes, oils).

[0039] The crystalline forms of maleate salts of the application can also be dosed with other active compounds that would be of benefit to a patient suffering from cancer, for example, other chemo agents or anti-biotics, or in conjunction with radiation therapy. These active compounds can be dosed with the compounds of the present application simultaneously or in sequence. The compounds of the present application can also be formulated to include the other active compound in the same dosage unit, for example both could be contained within one pill, table or capsule. Some of the possible types of active compounds that the compounds of the present application could be used in combination with are mitotic inhibitors, such as taxol and vinblastine, alkylating agents, such as cisplatin and cyclophosphamide, anti-metabolites, such as 5-fluorouracil and hydroxyurea, DNA intercalators, such as adriamycin and bleomycin, topoisomerase inhibitors, such as etoposide and camptothecin, antiangiogenic agents, such as angiostatin, and antiestrogens, such as tamoxifen. This application will be more fully described in conjunction with the following specific examples, which should not to be construed as

limiting the scope of this application. A skilled artisan will be able to re-arrange, combine, modify, or eliminate steps in the exemplified process, depending on process parameters and equipment.

[0040] The term "crystalline" as used herein, means having a regularly repeating arrangement of molecules or external face planes. Crystalline forms may differ with respect to thermodynamic stability, physical parameters, x-ray structure and preparation processes.

[0041] The term "amorphous" refers to a disordered solid state.

[0042] The term "anhydrous" as used herein, means a crystalline form containing less than about 1 % (w/w) of adsorbed moisture as determined by standard methods, such as a Karl Fisher analysis.

[0043] The term "essentially the same" means that variability typical for a particular method is taken into account. For example, with reference to X-ray diffraction peak positions, the term "essentially the same" means that typical variability in peak position and intensity are taken into account. One skilled in the art will appreciate that the peak positions (2θ) will show some variability, typically as much as $\pm 0.2^\circ$. Further, one skilled in the art will appreciate that relative peak intensities will show inter-apparatus variability as well as variability due to degree of crystallinity, preferred orientation, prepared sample surface and other factors known to those skilled in the art and should be taken as qualitative measures only.

[0044] Hygroscopicity tests of ((E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide in different acid salts have been carried out by the following method:

Hygroscopicity test

Step 1:

Take the dry glass weighing bottle which has a plug (outer diameter is 50mm, high is 15mm); placed in a suitable $25^\circ\text{C}\pm 1^\circ\text{C}$ constant temperature dryer (place a saturated solution of ammonium chloride or ammonium sulfate in the lower part) or artificial climate box (set the temperature to $25^\circ\text{C}\pm 1^\circ\text{C}$ and the relative humidity to $80\%\pm 2\%$) one day before the test, accurately weighting its weight(m_1).

Step 2:

Take appropriate amount of the test sample and lay it in the above weighing bottle, the thickness of the test sample is generally 1mm, accurately weighting its weight(m_2).

Step 3:

Open the weighing bottle and place it at the constant temperature and humidity as above-mentioned for 24 hours with its plug.

Step 4:

Accurately weighting its weight(m_3), including the weighing bottle and its plug.

5 Percentage of weight gain= $(m_3-m_2)/(m_2-m_1)*100\%$

Salt samples	m_1 (bottle)	m_2 (sample+ bottle)	m_3 (sample+ bottle)	weight gain (%)	Results
Hydrochloride acid salt	27.4334	27.4799	27.5016	46.67%	Highly wetting property
Citrate salt	30.5584	30.7966	30.8610	27.04%	Highly wetting property
L-malate salt	27.9296	28.4138	28.4930	16.36%	Highly wetting property
Sulphate salt	28.8232	29.0405	29.1190	36.13%	Highly wetting property
Maleate salt	31.23123	31.68383	31.68471	0.2%	Slightly arthroscopic

Definition:

Deliquesce: Absorb enough water to form liquid;

Highly wetting property: Percentage of weight gain is no less than 15%;

10 Humidity: Percentage of weight gain is less than 15% but no less than 2%;

Slightly arthroscopic: Percentage of weight gain is less than 2% but no less than 0.2%;

No or almost no arthroscopic: Percentage of weight gain is less than 0.2% .

[0045] Salts

Salt	Crystallinity by PXRD	PXRD pattern
Hydrochloride acid salt	amorphous	Fig. 6
Citrate salt	crystalline	Fig. 7
L-malate salt	amorphous	Fig. 8
Sulphate salt	amorphous	Fig. 9
Maleate salt	crystalline	Fig. 3

15

[0046] Bioavailability of ((E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide in maleate and citrate salt has been tested. SD rats (240-250 g, male, N=6; purchased from Sino-British SIPPR/BK Lab Animal Ltd, Shanghai, China) were administrated by I.V. : 5 mg/kg (5 mL/kg) via foot dorsal vein injection (N=3), PO: 10 mg/kg (10 mL/kg) via gavage (N=3); and the blood samples of the animals were collected at

20

the designated time points (predose, 0.0833h, 0.25h, 0.5h, 1h, 2h, 4h, 8h, 24h). The bioavailability of maleate and citrate are respectively 49.6% and 36.7%.

[0047] The above results has shown that ((E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl) amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide in maleate has more excellent physiochemical properties and better bioavailability than other salts, which are unexpected by a person skilled in the art.


[0048] Instrument and method


[0049] PXRD is performed in Rigaku UltimaIV diffractometer, copper target, $\lambda=1.5406\text{\AA}$; working voltage 40kv; working current: 40Ma; scan speed: 60.000 deg./min; scan range: 4.0000 -> 60.0000 deg.

[0050] Differential Scanning Calorimetry (DSC) is performed in US TA Q2000, and TGA in US TA Q2000.

[0051] FT-IR spectra were performed by using a Fourier transform infrared spectrophotometer, and potassium bromide (KBr) pellet.


[0052] Meanwhile, the following compounds and their salts such as sulphate, hydrochloride, L-malate, citrate, and maleate have been contemplated according to WO2013152135:





Synthesis and Preparation


[0053] Example 1. (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide sulfate



95% ethanol (4.0 ml) was added to (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide (500 mg, 0.99 mmol, 1.0 eq), followed sulfuric acid (101.9 mg, 1.04 mmol, 1.05 eq) in 95% ethanol (1.0 ml) was added dropwise to the reaction mixture. Then an amount of precipitate was founded. Another 95% (60 ml) was added to the reaction mixture and the reaction mixture was heated to 70°C. Filtered and the filtrate was heated to 70°C again. Then the reaction mixture was cooled to room temperature and The reaction mixture was crystallized at -10°C for 41.5h. Filtered the precipitated solid and dried at 40°C under vacuum for 1 hour to get the title compound (260 mg) as a yellow solid.

X-ray detection shows an amorphous structure to the compound as FIG. 9.


[0054] Example 2. Synthesis of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide hydrochloride



95% ethanol (5.0 ml) was added to (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide (500 mg, 0.99 mmol, 1.0 eq), followed hydrochloric acid (38.0 mg, 1.04 mmol, 1.05 eq) in 95% ethanol (1.0 ml) was added dropwise to the reaction mixture. The reaction mixture was heated to 70°C. Filtered and the filtrate was crystallized under -10°C for 44.5h. Filtered the precipitated solid and dried at 40°C under vacuum for 1 hour to get the title compound (96 mg) as a yellow solid.

X-ray detection shows an amorphous structure to the compound in FIG. 6.

[0055] Example 3. Synthesis of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide malate




(E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide (500 mg, 0.99 mmol, 1.0 eq), L-malic acid (139.4 mg, 1.04 mmol, 1.05 eq) and 95% ethanol (5.0 ml) was added to a 50 ml round-bottom flask. The reaction mixture was heated to 70°C. Filtered and the filtrate was crystallized under -10°C for 45.5h. A little of precipitate was founded and then the reaction mixture was evaporated under vacuum at 40°C to give the target (370 mg) as a yellow solid.

X-ray detection shows an amorphous structure to the compound in FIG.8

10

Example 4: synthesis of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide citrate



To a solution of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide (500 mg, 0.99 mmol, 1.0 eq), citric acid (198.8 mg, 1.04 mmol, 1.05 eq) and 95% ethanol (5.0 ml). The reaction mixture was heated to 70°C. Filtered and the filtrate was crystallized under -10°C for 45h. A little of precipitate was founded and then the reaction mixture was evaporated under vacuum at 40°C to give the target compound (610 mg) as a yellow solid.

X-ray detection shows an crystalline structure to the compound in FIG.7.

[0056] Example 5: Preparation of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate monohydrate.

(E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide free base (0.091 kg) is rinsed with a 10% solution of USP purified water in n-propanol (0.082 kg, 0.10 L) followed by the addition of water: n-propanol solution (0.74 kg, 0.90 L).

Maleic acid is added (1.01 equiv) and the mixture is rinsed with 10% water:n-propanol (0.082 kg, 0.10 L). The mixture is quickly heated to 50-60 °C and held for a minimum of 15 min. until a solution is obtained. The hot solution is clarified through a pre-heated 50-60 °C, 0.2 Mm filter cartridge and the filtrates are collected in a preheated 45-55 °C, 2 L multi-neck flask. The filter
5 cartridge is rinsed through with 10% water: n-propanol pre-heated to 45-55 °C (0.082 kg, 0.10 L). The solution is cooled over at least one hour to 40 °C and held at that temperature for 12 hours then cooled to room temperature (25 °C) over a minimum of four hours and held at that temperature for at least two hours. The mixture is filtered on a 12.5 cm diameter Buchner funnel for 5 min., then rinsed and washed with prefiltered 10% water: n-propanol solution (2 x
10 0.12 kg, 2 x 0.15 L). The cake is dammed and suction maintained until dripping essentially stops, about 1 h.

PXRD is shown in FIG.1.

[0057] Example 6: The product from Example 1 is dried (50 °C, 10 mm Hg, 24 h) to give crystalline, anhydrous (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-
15 4-(dimethylamino)but-2-enamide maleate.

PXRD is shown in FIG.3.

[0058] Example 7: Preparation of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl) amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate monohydrate.

To a solution of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-
20 (dimethylamino)but-2-enamide (38.0 g, 75.0 mmol, 1.0 eq) and n-propanol/H₂O (380 ml, V:V=9:1), maleic acid (8.7 g, 75.0 mmol, 1.0 eq) in n-propanol/H₂O (76 ml, V:V=9:1) was added to the reaction mixture. An amount of precipitate was founded, then the reaction mixture was heated to 65 °C. The solid was dissolved completely, then the reaction mixture was cooled to room temperature and stand for 20 hours. Filtered and filtrate was evaporated under vacuum to
25 get the crude product.

The crude product (14.0 g) was recrystallized in n-propanol/H₂O (240 ml, V:V=9:1) at 70 °C. The solid was dissolved completely, then the reaction mixture was cooled to room temperature and stand for 20.5 hours. Filtered and wash the cake with n-propanol/H₂O (20 ml, V:V=9:1) to get target product (12.9 g, wet).

PXRD as FIG.1.

[0059] Example 8: crystalline, anhydrous (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl) amino)quinolin-6-yl)-4- (dimethylamino)but-2-enamide maleate.

To a solution of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-

(dimethylamino)but-2-enamide(21.5 g, 42.4 mmol, 1.0 eq) and ethanol(300 ml). maleic acid (5.2 g, 44.8 mmol, 1.05 eq) was added to the reaction mixture. An amount of precipitate was founded, then the reaction mixture was heated to 70 °C. Another ethanol(1980 ml) was added to the reaction mixture in several times and the reaction temperature was keep at 70 °C.

- 5 Filtered and filtrate was cooled to room temperature, stop stirring and stand for 16-20 hours. Filtered and the solid was dried at room temperature for 24 hours to get the title compound.

PXRD as FIG.3.

CLAIMS

1. A maleate salt of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide.
- 5 2. The maleate salt of claim 1, which is monohydrate.
3. The maleate salt of claim 1, which is anhydrous.
4. The maleate salt of claim 1, which is characterized as: an anhydrous form, a monohydrate form, or a mixture of the anhydrous and the monohydrate forms.
5. The maleate salt of any one of claim 1-4, which is crystalline.
- 10 6. The maleate salt of claim 5, which is crystalline maleate salts, characterized by its powder X-ray diffraction (PXRD) pattern having characteristic peaks at about 8.1, 15.0, 17.6, and 23.6 degree of 2θ (± 0.2), preferably further characterized by its PXRD having additional peaks at about 9.0, 18.5, 22.7, 23.0, and 25.1, more preferably having essentially the same as shown in FIG. 3.
- 15 7 The maleate salt of claim 5, which is crystalline maleate monohydrate, characterized by its powder X-ray diffraction (PXRD) pattern having characteristic peaks at about 15.5, 16.8, 20.9, 24.4, 25.2 and 26.5 degree of 2θ (± 0.2), further characterized by its PXRD having additional peaks at about 8.7, 9.8, 14.3, 17.4, 19.3, 19.8, and 23.8, preferably having essentially the same as shown in FIG. 1.
- 20 8. The maleate salt of claim 7, which is characterized by its differential scanning calorimetry (DSC) thermogram having two endothermic peaks between about 153 °C and about 180 °C, preferably having essentially the same as shown in FIG. 2.
9. The maleate salt of claim 7, which is characterized by IR spectra comprising one or more peaks at about 3507.20, 3326.14, 3036.83, 2995.35, 2938.83, 2640.50, 2417.18, 2214.77, 25 1847.62, 1686.72, 1620.70, 1581.83, 1539.15, 1485.39, 1459.27, 1386.91, 1349.85, 1278.17, 1226.56, 1163.32, 1113.32, 1078.80, 1034.16, 979.59, 866.53, 829.88, 747.82, 700.14, 662.23, 556.48, and 487.55 cm^{-1} .
10. A method for preparing the maleate salt of claims 1-9, comprising the step of: mixing ((E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2- 30 enamide and maleic acid in a water-alcohol solution or an alcohol solution at an elevated temperature.
11. The method of Claim 10, further comprising the steps of: cooling said solution to precipitate said maleate salt and filtering said solution after cooling to obtain crystalline

(E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate.

12. A pharmaceutical composition comprising the maleate salt of any one of claims 1-9 and a pharmaceutically acceptable carrier.

5 13. A method for preventing, treating, or inhibiting cancer comprising, administering to a subject a therapeutically-effective amount of the maleate salt of any one of claims 1-9.

14. The method according to Claim 13, wherein said cancer is selected from at least one of: breast cancer, ovarian cancer, epidermoid tumors, colon cancer, prostate cancer, kidney cancer, bladder cancer, larynx cancer, esophagus cancer, stomach cancer, lung cancer, chronic

10 lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and multiple myeloma.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2018/116484

A. CLASSIFICATION OF SUBJECT MATTER

C07D 215/44(2006.01)i; A61K 31/4706(2006.01)i; A61P 35/00(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D 215/-, A61K 31/-; A61P 35/-

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CNABS;CNKI;VEN;REG;CAPLUS: maleate, quinolin+, zhang da wei/in, CAS RN: 1469746-55-1

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CN 104203242 A (ZHANG DA WEI) 10 December 2014 (2014-12-10) claims 1 and 6-14, the description, paragraphs [0028]-[0085] and [0097], example 1	1-14
Y	CN 104513200 A (JIANGSU SZYY GROUP PHARMACEUTICAL LTD) 15 April 2015 (2015-04-15) claims 1-9 and 12-16, the description, paragraphs [0005]-[0022], [0029]-[0035] and [0050]-[0064]	1-14
Y	CN 101203494 A (WYETH) 18 June 2008 (2008-06-18) the description, schemes 2 and 3, example 7	1-14
Y	CN 105367552 A (SUZHOU CRYSTAL PHARMATECH CO LTD) 02 March 2016 (2016-03-02) see the whole document	1-14
Y	CN 101918390 A (WYETH LLC) 15 December 2010 (2010-12-15) see the whole document	1-14

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

“A” document defining the general state of the art which is not considered to be of particular relevance

“E” earlier application or patent but published on or after the international filing date

“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

“O” document referring to an oral disclosure, use, exhibition or other means

“P” document published prior to the international filing date but later than the priority date claimed

“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

“&” document member of the same patent family

Date of the actual completion of the international search

29 January 2019

Date of mailing of the international search report

20 February 2019

Name and mailing address of the ISA/CN

National Intellectual Property Administration, PRC
6, Xitucheng Rd., Jimen Bridge, Haidian District, Beijing
100088
China

Authorized officer

XU,Chi

Facsimile No. (86-10)62019451

Telephone No. 62086349

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2018/116484

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **13 and 14**
because they relate to subject matter not required to be searched by this Authority, namely:

[1] Claims 13 and 14 relate to a method for treating diseases (see PCT Rule 39.1.(iv)), however, the search has been carried out and based on the use of the maleate salt of any one of claims 1-9 in the manufacture of corresponding medicaments
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/CN2018/116484

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)			Publication date (day/month/year)
CN	104203242	A	10 December 2014	EP	2833886	A1	11 February 2015
				CN	104203242	B	15 March 2017
				EP	2833886	A4	30 December 2015
				WO	2013152135	A1	10 October 2013
				US	9353062	B2	31 May 2016
				US	2015057312	A1	26 February 2015
CN	104513200	A	15 April 2015	CN	104513200	B	03 May 2017
CN	101203494	A	18 June 2008	NO	20076067	A	21 December 2007
				CA	2609186	A1	30 November 2006
				IL	187532	D0	20 March 2008
				NO	20076067	B	21 December 2007
				GT	200600213	A	12 January 2007
				ZA	200710148	A	25 September 2008
				PA	8676201	A1	31 March 2009
				AU	2006249600	A1	30 November 2006
				ZA	200710148	B	25 September 2008
				US	2006270668	A1	30 November 2006
				CR	9544	A	07 March 2008
				PE	14172006	A1	20 January 2007
				BR	PI0610147	A2	01 June 2010
				TW	200716557	A	01 May 2007
				KR	20080016671	A	21 February 2008
				RU	2007143161	A	10 July 2009
				JP	2008545688	A	18 December 2008
				AR	053872	A1	23 May 2007
				WO	2006127207	A1	30 November 2006
				EP	1883631	A1	06 February 2008
CN	105367552	A	02 March 2016	MX	2017009028	A	27 September 2017
				CN	107428727	A	01 December 2017
				EP	3243819	A1	15 November 2017
				CA	2973853	A1	14 July 2016
				IL	253360	D0	28 September 2017
				US	2018265495	A1	20 September 2018
				EP	3243819	A4	27 June 2018
				WO	2016110270	A1	14 July 2016
				JP	2018501289	A	18 January 2018
CN	101918390	A	15 December 2010	HK	1187619	A1	30 June 2017
				JP	2017043640	A	02 March 2017
				EP	2212311	A2	04 August 2010
				EP	2258698	A2	08 December 2010
				MX	2010004173	A	30 April 2010
				EP	2537843	B1	14 September 2016
				CN	106822127	A	13 June 2017
				IL	205024	A	30 April 2018
				JP	2013053170	A	21 March 2013
				EP	2258698	A3	16 February 2011
				RU	2010115089	A	27 November 2011
				KR	20100069708	A	24 June 2010
				US	8022216	B2	20 September 2011

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/CN2018/116484

Patent document cited in search report	Publication date (day/month/year)	Patent family member(s)	Publication date (day/month/year)
		EP 2626353 B1	23 November 2016
		JP 2018109071 A	12 July 2018
		JP 6412090 B2	24 October 2018
		CN 103554086 A	05 February 2014
		US 2009176827 A1	09 July 2009
		AR 103866 A2	07 June 2017
		KR 20160136474 A	29 November 2016
		TW 200934761 A	16 August 2009
		KR 20180041753 A	24 April 2018
		JP 5965640 B2	10 August 2016
		NZ 600349 A	20 December 2013
		US 2013281488 A1	24 October 2013
		AU 2008312474 B2	16 January 2014
		US 8394959 B2	12 March 2013
		IN 1135DEN2015 A	10 July 2015
		BR PI0818464 A2	05 January 2016
		NZ 616136 A	24 April 2015
		RU 2463300 C2	10 October 2012
		CA 2928071 C	25 April 2017
		KR 101208301 B1	05 December 2012
		US 2011313166 A1	22 December 2011
		US 9139558 B2	22 September 2015
		KR 20150039872 A	13 April 2015
		EP 2537843 A3	13 March 2013
		PA 8800701 A1	15 May 2009
		CA 2928071 A1	23 April 2009
		ES 2602123 T3	17 February 2017
		MX 349332 B	21 July 2017
		JP 2015127352 A	09 July 2015
		MX 342681 B	07 October 2016
		IL 258440 D0	31 May 2018
		US 2017320852 A1	09 November 2017
		EP 2537843 A2	26 December 2012
		EP 2617719 A1	24 July 2013
		SG 185312 A1	29 November 2012
		IL 205024 D0	30 November 2010
		EP 2626353 A1	14 August 2013